FDA grants accelerated approval to AstraZeneca’s Ultomiris for primary IgA nephropathy
AstraZeneca announced that the U.S. Food and Drug Administration granted accelerated approval for Ultomiris (ravulizumab) to treat primary immunoglobulin A nephropathy (IgAN). The approval is based on an interim analysis showing a 43.4% reduction in proteinuria versus placebo after 34 weeks. AstraZeneca will seek full traditional approval after completing a 106‑week Phase III trial. The indication targets an estimated 200,000 U.S. patients, about half of whom face a high risk of kidney failure within ten years.
Why it matters
The new indication adds a rare‑kidney‑disease market to Ultomiris, potentially expanding AstraZeneca’s revenue base. Investors should watch for future sales data and the outcome of the confirmatory trial, which will determine whether the drug receives full approval.
Key facts
- 1The FDA granted accelerated approval for Ultomiris on October 21 2026. gurufocus.com
- 2Ultomiris (ravulizumab) is approved to reduce proteinuria in adults with primary IgAN. gurufocus.com
- 3An interim analysis showed a 43.4% reduction in proteinuria compared with placebo after 34 weeks. gurufocus.com
- 4AstraZeneca plans to pursue traditional approval after completing a 106‑week Phase III trial. investing.com
- 5Over 200,000 patients in the United States have IgAN, with about half at high risk of kidney failure within a decade. investing.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.